FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589358629> ?p ?o ?g. }

• W2589358629 endingPage "1057" @default.
• W2589358629 startingPage "1043" @default.
• W2589358629 abstract "Summary Background Biosimilars of anti‐tumour necrosis factor ( TNF )‐α agents have now become clinically available for the treatment of inflammatory bowel diseases ( IBD ). Aim To perform a systematic review and meta‐analysis to evaluate the efficacy and safety of biosimilars of anti‐ TNF ‐α agents in patients with IBD . Methods Electronic databases were searched. The outcomes were the pooled rates of clinical response or remission, sustained clinical response or remission, and adverse events in patients with IBD induced with or switched to biosimilars of anti‐ TNF ‐α agents. Results Eleven observational studies reporting outcomes in 829 patients treated with biosimilar of infliximab ( CT ‐P13) were identified. The pooled rates of clinical response among Crohn's disease ( CD ) and ulcerative colitis ( UC ) at 8–14 weeks were 0.79 (95% confidence interval ( CI ) = 0.65–0.88) and 0.74 (95% CI = 0.65–0.82), respectively, and at 24–30 weeks were 0.77 (95% CI = 0.63–0.86) and 0.77 (95% CI = 0.67–0.85) respectively. Adverse events were rare ( CD , 0.08 (95% CI = 0.02–0.26); UC , 0.08 (95% CI = 0.03–0.17)). The pooled rates of sustained clinical response among CD and UC after switching from infliximab to CT ‐P13 at 30–32 weeks were 0.85 (95% CI = 0.71–0.93) and 0.96 (95% CI = 0.58–1.00), respectively, and at 48–63 weeks were 0.75 (95% CI = 0.44–0.92) and 0.83 (95% CI = 0.19–0.99) respectively. Adverse events were rare ( CD , 0.10, 95% CI = 0.02–0.31; UC , 0.22, 95% CI = 0.04–0.63). Conclusions CT ‐P13 was associated with excellent clinical efficacy and safety profile, supporting its use in the treatment of IBD ." @default.
• W2589358629 created "2017-03-03" @default.
• W2589358629 creator A5031356877 @default.
• W2589358629 creator A5033914337 @default.
• W2589358629 creator A5042178093 @default.
• W2589358629 creator A5061244847 @default.
• W2589358629 creator A5063018115 @default.
• W2589358629 creator A5082236119 @default.
• W2589358629 date "2017-02-26" @default.
• W2589358629 modified "2023-10-18" @default.
• W2589358629 title "Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases" @default.
• W2589358629 cites W1515981258 @default.
• W2589358629 cites W1827882046 @default.
• W2589358629 cites W1851453522 @default.
• W2589358629 cites W1924255685 @default.
• W2589358629 cites W1964435302 @default.
• W2589358629 cites W1965199489 @default.
• W2589358629 cites W1967570746 @default.
• W2589358629 cites W1979423827 @default.
• W2589358629 cites W1979942124 @default.
• W2589358629 cites W1991247706 @default.
• W2589358629 cites W2015169835 @default.
• W2589358629 cites W2022888597 @default.
• W2589358629 cites W2025398922 @default.
• W2589358629 cites W2031349966 @default.
• W2589358629 cites W2087727538 @default.
• W2589358629 cites W2093884168 @default.
• W2589358629 cites W2103507212 @default.
• W2589358629 cites W2105792933 @default.
• W2589358629 cites W2119605658 @default.
• W2589358629 cites W2126930838 @default.
• W2589358629 cites W2128694968 @default.
• W2589358629 cites W2130173462 @default.
• W2589358629 cites W2137961216 @default.
• W2589358629 cites W2139366207 @default.
• W2589358629 cites W2146963207 @default.
• W2589358629 cites W2151444904 @default.
• W2589358629 cites W2157823046 @default.
• W2589358629 cites W2158925111 @default.
• W2589358629 cites W2170715266 @default.
• W2589358629 cites W2171297959 @default.
• W2589358629 cites W2208243538 @default.
• W2589358629 cites W2251103812 @default.
• W2589358629 cites W2279977120 @default.
• W2589358629 cites W2308369648 @default.
• W2589358629 cites W2313671791 @default.
• W2589358629 cites W2314763045 @default.
• W2589358629 cites W2317502128 @default.
• W2589358629 cites W2324319956 @default.
• W2589358629 cites W2324634360 @default.
• W2589358629 cites W2340224273 @default.
• W2589358629 cites W2342216265 @default.
• W2589358629 cites W2397773641 @default.
• W2589358629 cites W2398448526 @default.
• W2589358629 cites W2407777894 @default.
• W2589358629 cites W2468996569 @default.
• W2589358629 cites W2480851940 @default.
• W2589358629 cites W2515111437 @default.
• W2589358629 cites W2550274663 @default.
• W2589358629 cites W4240919941 @default.
• W2589358629 doi "https://doi.org/10.1111/apt.13990" @default.
• W2589358629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28239873" @default.
• W2589358629 hasPublicationYear "2017" @default.
• W2589358629 type Work @default.
• W2589358629 sameAs 2589358629 @default.
• W2589358629 citedByCount "91" @default.
• W2589358629 countsByYear W25893586292017 @default.
• W2589358629 countsByYear W25893586292018 @default.
• W2589358629 countsByYear W25893586292019 @default.
• W2589358629 countsByYear W25893586292020 @default.
• W2589358629 countsByYear W25893586292021 @default.
• W2589358629 countsByYear W25893586292022 @default.
• W2589358629 countsByYear W25893586292023 @default.
• W2589358629 crossrefType "journal-article" @default.
• W2589358629 hasAuthorship W2589358629A5031356877 @default.
• W2589358629 hasAuthorship W2589358629A5033914337 @default.
• W2589358629 hasAuthorship W2589358629A5042178093 @default.
• W2589358629 hasAuthorship W2589358629A5061244847 @default.
• W2589358629 hasAuthorship W2589358629A5063018115 @default.
• W2589358629 hasAuthorship W2589358629A5082236119 @default.
• W2589358629 hasBestOaLocation W25893586291 @default.
• W2589358629 hasConcept C126322002 @default.
• W2589358629 hasConcept C17991360 @default.
• W2589358629 hasConcept C197934379 @default.
• W2589358629 hasConcept C2777138892 @default.
• W2589358629 hasConcept C2778260677 @default.
• W2589358629 hasConcept C2779134260 @default.
• W2589358629 hasConcept C2780132546 @default.
• W2589358629 hasConcept C2780479503 @default.
• W2589358629 hasConcept C44249647 @default.
• W2589358629 hasConcept C59491497 @default.
• W2589358629 hasConcept C71924100 @default.
• W2589358629 hasConcept C90924648 @default.
• W2589358629 hasConcept C95190672 @default.
• W2589358629 hasConceptScore W2589358629C126322002 @default.
• W2589358629 hasConceptScore W2589358629C17991360 @default.
• W2589358629 hasConceptScore W2589358629C197934379 @default.
• W2589358629 hasConceptScore W2589358629C2777138892 @default.

• next